DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, J.M. | ko |
dc.contributor.author | Cho, S.Y. | ko |
dc.contributor.author | Rhu, J. | ko |
dc.contributor.author | Jung, M. | ko |
dc.contributor.author | Her, J.H. | ko |
dc.contributor.author | Lim, O. | ko |
dc.contributor.author | Choi, G.-S. | ko |
dc.contributor.author | Shin, Eui-Cheol | ko |
dc.contributor.author | Hwang, Y.-K. | ko |
dc.contributor.author | Joh, J.-W. | ko |
dc.date.accessioned | 2021-12-24T06:45:32Z | - |
dc.date.available | 2021-12-24T06:45:32Z | - |
dc.date.created | 2021-12-23 | - |
dc.date.created | 2021-12-23 | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Annals of Hepato-Biliary-Pancreatic Surgery, v.25, no.2, pp.206 - 214 | - |
dc.identifier.issn | 2508-5778 | - |
dc.identifier.uri | http://hdl.handle.net/10203/291145 | - |
dc.description.abstract | Backgrounds/Aims: Fewer reports have been published regarding hepatectomy patients with solitary hepatocellular carcinoma (HCC) who received immunotherapeutic agents as adjuvant therapy. We evaluated the safety and efficacy of ex vivo-expanded allogenic natural killer (NK) cells in those patients with modified International Union Against Cancer (UICC) stage T3. Methods: From August 2014 to October 2015, five patients who underwent hepatic resection received ex vivo-expanded allogenic NK cells. Patients received five rounds of NK cells (2-3×107 cells/kg) at postoperative 4, 6, 8, 12, and 16 weeks. This study is registered with ClinicalTrials.gov, number NCT02008929. Results: The median age of the five patients (three men and two women) was 44.8 years (range, 36-54 years). All had hepatitis B virus-related HCC, and the median tumor size was 2.2 cm (range, 2.1-8.2 cm). None of the patients had any adverse events. HCC recurrence developed in two patients at one year after hepatic resection, but four patients were alive at 3 years. The two recurrence-free patients showed a higher ratio of CD8+ T lymphocyte populations before and after administration of ex vivo-expanded allogenic NK cells compared with the three patients who experienced recurrence. Conclusions: Immunotherapy using ex vivo-expanded allogenic NK cells in hepatectomy patients can be used safely. Further studies should be investigated for efficacy. (Ann Hepatobiliary Pancreat Surg 2021;25:206-214). © 2021 by The Korean Association of Hepato-Biliary-Pancreatic Surgery. | - |
dc.language | English | - |
dc.publisher | Korean Association of Hepato-Biliary-Pancreatic Surgery | - |
dc.title | Adjuvant therapy using ex vivo-expanded allogenic natural killer cells in hepatectomy patients with hepatitis b virus related solitary hepatocellular carcinoma: Mg4101 study | - |
dc.type | Article | - |
dc.identifier.scopusid | 2-s2.0-85115318512 | - |
dc.type.rims | ART | - |
dc.citation.volume | 25 | - |
dc.citation.issue | 2 | - |
dc.citation.beginningpage | 206 | - |
dc.citation.endingpage | 214 | - |
dc.citation.publicationname | Annals of Hepato-Biliary-Pancreatic Surgery | - |
dc.identifier.doi | 10.14701/ahbps.2021.25.2.206 | - |
dc.identifier.kciid | ART002719097 | - |
dc.contributor.localauthor | Shin, Eui-Cheol | - |
dc.contributor.nonIdAuthor | Kim, J.M. | - |
dc.contributor.nonIdAuthor | Cho, S.Y. | - |
dc.contributor.nonIdAuthor | Rhu, J. | - |
dc.contributor.nonIdAuthor | Jung, M. | - |
dc.contributor.nonIdAuthor | Her, J.H. | - |
dc.contributor.nonIdAuthor | Lim, O. | - |
dc.contributor.nonIdAuthor | Choi, G.-S. | - |
dc.contributor.nonIdAuthor | Hwang, Y.-K. | - |
dc.contributor.nonIdAuthor | Joh, J.-W. | - |
dc.description.isOpenAccess | Y | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | Efficacy | - |
dc.subject.keywordAuthor | Hepatocellular carcinoma | - |
dc.subject.keywordAuthor | Immunotherapy | - |
dc.subject.keywordAuthor | Natural killer cells | - |
dc.subject.keywordAuthor | Safety | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.